BAY3498264

BAY3498264 is an investigational oral small molecule drug developed by Bayer. It acts as a selective inhibitor of the protein son of sevenless homolog 1 (SOS1), which plays a key role in activating KRAS, a commonly mutated oncogene in human cancers. By inhibiting SOS1, BAY3498264 aims to disrupt the MAPK signaling pathway that regulates cell proliferation and tumor growth. The drug is being evaluated primarily for its potential to treat advanced solid tumors harboring KRAS G12C mutations, including non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer. In clinical studies, it is administered both as monotherapy and in combination with sotorasib (a KRAS G12C inhibitor) to potentially enhance treatment efficacy and prolong response duration[1][2][3][4][5][6][7].

Brand names

BAY 3498264BAY3498264BAY-3498264

Other names

BAY-3498264BAY3498264BAY 3498264